Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU Indication Extensions On Cards For Taltz, Truvada and Yervoy

Executive Summary

Eli Lilly, Gilead and Bristol-Myers Squibb can look forward to product indication extensions after getting the OK from the European Medicines Agency’s CHMP. Other companies seeking extensions will be asked for more information.

Advertisement

Related Content

April CHMP Meeting: Disappointment In Advance For AB Science, Gilead Hopeful On Biktarvy
EU Approval In Sight For New ATMP, Products For XLH And Diabetes, And 2nd Biosimilar Herceptin
Pipeline Watch: Phase III Studies of CSL112 And RT-100 Imminent

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS122165

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel